SlideShare ist ein Scribd-Unternehmen logo
1 von 62
Downloaden Sie, um offline zu lesen
Leukemia
Leukemia
About the Disease
 Leukemia, lymphoma and myeloma are
cancers that originate in the bone marrow
(leukemia & myeloma) or in lymphatic tissues
(lymphoma).
Different Types of Blood Cancers
 Leukemia
 Non-Hodgkin Lymphoma
 Hodgkin Lymphoma
 Myeloma
 Myelodysplastic Syndromes
What is Leukemia?
 Leukemia is cancer
found in the blood cells
 There are many types
of Leukemia
 They are classified by
how quickly they
progress and what type
of cell they affect
 Leukemia is causes
when there is an
imbalance of healthy
unhealthy blood cells in
the body
 This occur when one
cell awry and the body
begins to produce large
numbers of this cell
What Is Leukemia?
 Cancer of the white blood cells
 Acute or Chronic
 Affects ability to produce normal blood cells
 Bone marrow makes abnormally large
number of immature white blood cells called
blasts
What is Leukemia
 Greek word which means “white blood”
 Leukemia is when cells spread rapidly and destroy
living tissue.
 It grows/invades the bone marrow which is the
factory of blood and replaces normal blood elements
with cancer cells.
 Cancer cells replace all bone marrow cells which
causes infection and bleeding problems.
 Leukemia is basically white blood cells that don’t
work well and cause trouble.
Continued
 Millions of immature and useless white blood cells
are produced which makes it harder to kill cancer
cells and preserve the good/healthy ones.
 Leukemia causes change in cells, DNA, and gene.
 If the blood matches with donator then you are
curried.
 Bone marrow is spongy tissue that fills in the center
core of bone.
 There are 4 different types of Leukemia.
Types of Leukemia
 Based on how quickly the
disease develops it is
classified as either acute or
chronic
 In Acute Leukemia the
white blood cells tend to
develop more rapidly and
very immature
 In Chronic Leukemia the
cells tend to develop more
slowly
 They are also classified by
which type of white bloods
cells are affected
 If the lymphoid cells are
affected the disease is
referred to as
Lymphocytic Leukemia
 If the myeloid cells are
affected it is called
Myelongenous Leukemia
Types of Leukemia
 Acute lymphoblastic Leukemia (ALL)
 Acute myeloblastic Leukemia (AML)
 Chronic lymphocyte Leukemia (CLL)
 Chronic myeloid Leukemia (CML)
Demographics of Leukemia
Patients (2001 Data)
ALL
11%
CLL
26%
AML
31%
CML
15%
others
17%
Total Reported Cases = 31,500
Sources from Leukemia, Lyphoma,
Myeloma Facts 2001
CLL=Chronic
Lymphocytic
ALL=Acute
Lymphocytic
CML=Chronic
Mylogenous
AML=Acute
Mylogenous
Chronic and Acute
Chronic Leukemia:
 Progress slowly (runs a slow course)
 Not immediately fatal.
Acute Leukemia:
 Progress rapidly (runs a fast course)
 Life expectancy short without treatment.
Lymphocyte and Myeloid
Lymphocyte:
 Increase in white blood cells produced in lymph
nodes and bone marrow.
 Strikes without any warning.
Myeloid:
 Increase in white blood cells produced exclusively in
the bone marrow.
 Strikes without any warning.
Acute Myeloid Leukemia
(AML):
 Mixed group of disease
 It means “marrow like” and in this context it
simply means arising from developing blood
cells.
 This type of leukemia runs a rapid course.
Acute Lymphoblast Leukemia
(ALL):
 Group of different diseases
 A complexity of which is still trying to be
unraveled
 Reached a point where not all are being
treated the same.
 This type of Leukemia runs a rapid course.
Chronic Myeloid Leukemia
(CML):
 Characterized by increased production of
granulocytes in the bone marrow.
 Usually associated with a specific
chromosomal abnormality called the
Philadelphia chromosome
 Progresses slowly
Chronic Lymphocyte Leukemia
(CLL):
 This type of cancer is so rare it could be said
not to arise at all in the first two decades of
life.
 Starts of in the Bone marrow
 This type of cancer runs a slow course giving
more time to live.
Risk Factors
 As of now we do not know
the exact cause of Leukemia
 Exposure to these have been
identified as risk factors
 High energy radiation
 Some genetic syndromes
 People working with chemical
benzene for a long period of
time
Causes
 High level radiation/toxin exposure
 Viruses
 Genes
 Chemicals
 Mostly unknown
 Can’t be caught
Development of Leukemia in the
Bloodstream
Stage 1- Normal Stage 2- Symptoms Stage 3- Diagnosis
Stage 4- Worsening
Stage 5a- Anemia
Stage 5b- Infection
Legend
White Cell
Red Cell
Platelet
Blast
Germ Sources from Leukemia, by D. Newton and D. Siegel
Effects On the Body
 Attacks the immune system
 Infections
 Anemia
 Weakness
 No more regular white blood cells, red blood cells,
and platelets
 Blasts clog blood stream and bone marrow
Symptoms
 When there are excessive white blood cells -
-> Infections
 When there are few red blood cells:
Paleness --> Anemia
 When there are few platelets --> Excessive
bleeding
Signs Of Leukemia
Most of the symptoms of leukemia are similar to those of a
common illness such as the flu. The symptoms will vary
according to the type of leukemia.
 Tired
 Frequent infections
 Easy bruising or bleeding
 Bone tenderness
 Headache
 Enlarged lymph nodes
 Low red blood count
 Pale skin
 Poor appetite
Tests For Diagnosis
 Finger prick
 Blood sample
 Blood dye
 Bone marrow sample
 Spinal Tap/Lumbar Puncture
Diagnosis
 As immature cells increase in the body leads to lower
amounts of red blood cells and platelet cells
 The low amounts of red blood cells cause patient to be
tired and pale
 Low amounts of platelet cells cause the patient to easily
bruise or bleed
 During a physical exam the doctor detects swollen spleen,
liver, or lymph nodes
 Then there is a blood test conducted to see if it is leukemia
 The type of Leukemia is determined after bone marrow is
extracted and tested
Diagnosis
 Most commonly leukemia is diagnosed by a
blood test to count the number of red cells,
white cells and platelets. A biopsy of the
bone marrow may also be performed
Pictures Of Blood
Normal human blood
White Cell Red Cell
Platelet
Blood with leukemia
Blasts
Red Cell
Platelet
White Cell
Sources from Arginine.umdnj.edu
Sources from beyond2000.com
leukemias.ppt
Diagnosis
Requires all of the following diagnostic
components:
a) Documentation of bone marrow
infiltration
b) Myeloid origin of the leukemic cells
c) FAB/WHO classification of the
leukemia
d) Karyotypic analysis
Differential Diagnosis
 chronic myelogenous leukemia
 other myeloproliferative disorders
 reactive leukocytosis: leukemoid reaction
 acute leukemia
Philadelphia Chromosome
t(9;22)(q34;q11)
BCR-ABL Gene Product
BCR-ABL p210 Fusion Protein
Activity
 Higher tyrosine kinase activity.
– Increases progenitor cells, reduces the pool of
stem cells. Semin Hematol 1988;25:1-19.
– Defective cytoadherence. Hematol Oncol Clin North
Am 1988;12:1-29.
– Suppression of apoptosis. Blood 1994;83:1575-85.
BCR-ABL p210 Fusion Protein
Evidence of its role in CML
 In vitro: cause factor-independent,
leukemogenic cell growth in hematopoietic
cell lines.
 In vivo: generate in mice CML-like syndrome.
Science 1990;247:824-30.
FAB Classifications
M0: minimally differentiated
M1: without maturation
M2: with maturation. May have t(8;21) translocation.
M3: promyelocytic. Good prognosis. Can be associated
w/ t(15;17).
M4: myelomonocytic; assoc. w/ t(16;16) or
inv(16)(p13q22).
M5: monoblastic
M6: erythroleukemia
M7: megakaryoblastic. Poor overall survival.
leukemias.ppt
leukemias.ppt
leukemias.ppt
leukemias.ppt
leukemias.ppt
leukemias.ppt
leukemias.ppt
leukemias.ppt
leukemias.ppt
Clinical Course
 Median survival: 3.5~8 yr.
 Chronic phase: 3~4 yr.
 Accelerated phase (15%): 3~6 mo, then enters acute
phase.
 Acute phase (blast crisis), 25% in each year, findings:
blasts > 30%, cytogenetic changes other than Ph
chromosome, progression likes acute leukemia. 70%
enters AML, 30% ALL.
Prognosis
“Good risk”: favorable karyotype, including
t(8;21), t(15;17), inv(16)/t(16;16)/del(16q)
or FAB subtype M3
“Poor risk”: adverse karyotype or resistant
disease after first course of chemo (i.e. >15%
blasts in post-tx bone marrow bx)
5-yr survival for good, standard, and poor risk
patients 70, 48, and 15% respectively.
Relapse rates are 33, 50, and 78%
respectively.
Treatment
 As of yet there is no
cure for Leukemia
 Many advances have
been made in the past
couple years
 The survival rate of
children with Acute
Lymphocytic is around
82%
Treatments include:
 Chemotherapy
 Radiotherapy
 Immunotherapy
 Bone marrow transplant
Research
 New drugs
 Cord blood and planceta
Treatment
 Depending on the type of cancer treatments may
vary. Treatments of leukemia may include
chemotherapy, radiation therapy, or bone
marrow transplant. They also treat leukemia
patients with the infusion of healthy blood cells
and platelets. During and after the treatment
blood counts are done to see if the patient is
being controlled or in remission.
Treatments
 Blood and marrow stem cell transplantation.
 Research.
 Development of new drugs.
 Immunotherapy.
 Vaccines.
 Reversal of multidrug resistance.
 Gene therapy.
Management (1)
 Chronic phase
– Hydroxyurea or busulfan, relieves symptoms and
control of disease.
– Interferon-a: 20% cytogenetic response,
prolongation of survival. . It can gain 20 more
months survival than C/T. This advantage must be
weighed against its significant side effects.
Management (2)
BMT or PBSCT
 Allogeneic bone marrow transplantation in
the chronic phase is the only therapy known
to cure CML
5YS > 50%, relapse < 20%, 20~40% BMT
related death in the first year.
 It should be done as soon as possible for
patients
– Chronic phase.
– <50 years old.
– Has an HLA-identical sibling.
Management (3)
STI571
 STI 571:Inhibitors of the BCR-ABL fusion proteins
(tyrosine kinase)
 After six months of therapy with Glivec (STI571), preliminary findings
showed that half of 290 patients tested were improving. They had
what's known as a cytogenic remission -- a reduction in the
'Philadelphia Chromosome' which causes the disease.
 "In these patients we found a very high response rate, there was some
response seen in 91 percent of the patients," said Dr. Talpaz of the
M.D. Anderson Cancer Center. "Some of the patients returned to the
chronic phase of the disease."
Allogeneic Stem Cell Transplantation
 eradicates of the marrow cells (marrow-
ablating C/T or R/T)
 implantation of allogeneic stem cells
 homing of the stem cells to the marrow cavity
 growth of the stem cells and recovery of the
blood cells
Complications of SCT
 rejection, graft failure
 graft-versus-host disease
 infection
 VOD
 obliterative bronchiolitis
 sepsis
 relapse of disease
GVHD
(Graft versus Host Disease)
 Immunologic reaction of donor lymphocytes
to “foreign” antigens present on the surface
of host cells
 “foreign” antigens:
– HLA antigens
– “minor” antigens not detected by current typing
techniques
Acute GVHD (1) incidence
 Within the first 3 months after BMT
 20~50% of HLA-identical, 80% of HLA non-
identical recipients
 incidence increases with
– patient age
– degree of HLA disparity
Acute GVHD (2)manifestations
 Histology: lymphocytic infiltration of the epidermis
and GI tract
 fever
 dermatitis: diffuse macular dermatitis, bullas,
desquamation
 enteritis: cramping abdominal pain, watery to bloody
diarrhea
 hepatitis: jaundice, cholestasis, hepatocellular
necrosis
 infection: frequently related to mortality
 hyperacute GVHD (no prophylaxis): 7 days after BMT:
exfoliative dermatitis, shock, hyperpyrexia
Chronic GVHD (1) incidence
 develops > 3 months after BMT
 20~50% of allografts, usually following acute
GVHD
 20~30% develops de novo, without prior
acute GVHD
Chronic GVHD (2)
manifestations like collagen diseases
 skin: pigmentation, sclerosis
 mucosa: lichenoid oral plaque, esophagitis,
polyserositis, oral and eye sicca syndrome
 liver: elevated ALP and GOT in 90% cases
 chronic wasting due to anorexia
 chronic pulmonary disease: 10~20% (diffuse interstitial
pnuemonitis and obliterative bronchiloitis)
 death usually caused by infection, low mortality
related to de novo onset & less tissue involvement.
Blast Crisis
 30% ALL, 70% AML
 Treatment likes de novo acute leukemia with poor
success.
 Chance of achieving remission is possible in ALL,
which may last 4~8 months, but low in AML.
 Survival is usually 2~4 months.
CML in Blast Crisis

Más contenido relacionado

Was ist angesagt?

Myelodysplastic syndrome by dr narmada
Myelodysplastic syndrome by dr narmadaMyelodysplastic syndrome by dr narmada
Myelodysplastic syndrome by dr narmadaNarmada Tiwari
 
Chronic lymphocytic leukemia
Chronic lymphocytic leukemiaChronic lymphocytic leukemia
Chronic lymphocytic leukemiaJasmine John
 
Acute myeloid leukemia
Acute myeloid leukemiaAcute myeloid leukemia
Acute myeloid leukemiaDR RML DELHI
 
Chronic Lymphocytic Leukemia
Chronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia
Chronic Lymphocytic LeukemiaDrAyush Garg
 
Pathogenesis and treatment of Chronic Myeloid Leukemia
Pathogenesis and treatment of Chronic Myeloid LeukemiaPathogenesis and treatment of Chronic Myeloid Leukemia
Pathogenesis and treatment of Chronic Myeloid LeukemiaAlok Gupta
 
Non hodgkin lymphoma
Non hodgkin lymphomaNon hodgkin lymphoma
Non hodgkin lymphomaVijay Shankar
 
Multiple myeloma final 2018 updated
Multiple myeloma final 2018 updatedMultiple myeloma final 2018 updated
Multiple myeloma final 2018 updatedAmrinderSingh248
 
Neoplasia ospe rapid review
Neoplasia ospe rapid reviewNeoplasia ospe rapid review
Neoplasia ospe rapid reviewdrabbasnaseem
 
Neoplasia Robbin's path
Neoplasia Robbin's pathNeoplasia Robbin's path
Neoplasia Robbin's pathPrasad CSBR
 
Aml and all by asif.ppt.jjj
Aml and all by asif.ppt.jjjAml and all by asif.ppt.jjj
Aml and all by asif.ppt.jjjAsif Zeb
 
Acute Myeloid Leukemia
Acute Myeloid LeukemiaAcute Myeloid Leukemia
Acute Myeloid LeukemiaAli Swailmeen
 

Was ist angesagt? (20)

Myelodysplastic syndrome by dr narmada
Myelodysplastic syndrome by dr narmadaMyelodysplastic syndrome by dr narmada
Myelodysplastic syndrome by dr narmada
 
Blood cancer
Blood cancerBlood cancer
Blood cancer
 
Acute leukemia; imtiaz
Acute leukemia; imtiazAcute leukemia; imtiaz
Acute leukemia; imtiaz
 
Chronic lymphocytic leukemia
Chronic lymphocytic leukemiaChronic lymphocytic leukemia
Chronic lymphocytic leukemia
 
ACUTE LEUKEMIA
ACUTE LEUKEMIAACUTE LEUKEMIA
ACUTE LEUKEMIA
 
chronic myeloid leukemia
chronic myeloid leukemiachronic myeloid leukemia
chronic myeloid leukemia
 
Vascular tumors
Vascular tumorsVascular tumors
Vascular tumors
 
Chronic Leukaemia
Chronic LeukaemiaChronic Leukaemia
Chronic Leukaemia
 
Acute myeloid leukemia
Acute myeloid leukemiaAcute myeloid leukemia
Acute myeloid leukemia
 
Chronic Lymphocytic Leukemia
Chronic Lymphocytic LeukemiaChronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
 
Pathogenesis and treatment of Chronic Myeloid Leukemia
Pathogenesis and treatment of Chronic Myeloid LeukemiaPathogenesis and treatment of Chronic Myeloid Leukemia
Pathogenesis and treatment of Chronic Myeloid Leukemia
 
Parasites in histopathology
Parasites in histopathologyParasites in histopathology
Parasites in histopathology
 
Non hodgkin lymphoma
Non hodgkin lymphomaNon hodgkin lymphoma
Non hodgkin lymphoma
 
Amyloidosis
AmyloidosisAmyloidosis
Amyloidosis
 
Multiple myeloma final 2018 updated
Multiple myeloma final 2018 updatedMultiple myeloma final 2018 updated
Multiple myeloma final 2018 updated
 
Neoplasia ospe rapid review
Neoplasia ospe rapid reviewNeoplasia ospe rapid review
Neoplasia ospe rapid review
 
Neoplasia Robbin's path
Neoplasia Robbin's pathNeoplasia Robbin's path
Neoplasia Robbin's path
 
Aml and all by asif.ppt.jjj
Aml and all by asif.ppt.jjjAml and all by asif.ppt.jjj
Aml and all by asif.ppt.jjj
 
Acute Myeloid Leukemia
Acute Myeloid LeukemiaAcute Myeloid Leukemia
Acute Myeloid Leukemia
 
Hodgkin’s lymphoma
Hodgkin’s lymphomaHodgkin’s lymphoma
Hodgkin’s lymphoma
 

Ähnlich wie leukemias.ppt (20)

Leukemia
LeukemiaLeukemia
Leukemia
 
Leukemia
Leukemia Leukemia
Leukemia
 
Leukemia
LeukemiaLeukemia
Leukemia
 
Leukemia
LeukemiaLeukemia
Leukemia
 
Leukemia
LeukemiaLeukemia
Leukemia
 
leukemia
leukemialeukemia
leukemia
 
Leukemia english
Leukemia englishLeukemia english
Leukemia english
 
Leukaemia for bds
Leukaemia for bdsLeukaemia for bds
Leukaemia for bds
 
Leukemia and its types presentation 1
Leukemia and its types presentation 1Leukemia and its types presentation 1
Leukemia and its types presentation 1
 
Leukemia by waheed javed
Leukemia by waheed javedLeukemia by waheed javed
Leukemia by waheed javed
 
ACUTE LEUKAEMIA.pptx
ACUTE  LEUKAEMIA.pptxACUTE  LEUKAEMIA.pptx
ACUTE LEUKAEMIA.pptx
 
Lukemia in children
Lukemia in children Lukemia in children
Lukemia in children
 
Leukemia & lymphoma
Leukemia & lymphomaLeukemia & lymphoma
Leukemia & lymphoma
 
Myeloproliferative Neoplasms
Myeloproliferative NeoplasmsMyeloproliferative Neoplasms
Myeloproliferative Neoplasms
 
BLOOD CANCER
BLOOD CANCERBLOOD CANCER
BLOOD CANCER
 
lecture leukemia.ppt
lecture leukemia.pptlecture leukemia.ppt
lecture leukemia.ppt
 
Acute Leukemia.pptx
Acute Leukemia.pptxAcute Leukemia.pptx
Acute Leukemia.pptx
 
Leukemias
LeukemiasLeukemias
Leukemias
 
Leukemia , causes, clinical features, raktarbud
Leukemia , causes, clinical features, raktarbud Leukemia , causes, clinical features, raktarbud
Leukemia , causes, clinical features, raktarbud
 
Leukemia.pptx
Leukemia.pptxLeukemia.pptx
Leukemia.pptx
 

Último

The Role of Non-Banking Financial Companies (NBFCs).pdf
The Role of Non-Banking Financial Companies (NBFCs).pdfThe Role of Non-Banking Financial Companies (NBFCs).pdf
The Role of Non-Banking Financial Companies (NBFCs).pdfChampak Jhagmag
 
renaltumors upasana sahu Group 50.pptxism
renaltumors upasana sahu Group 50.pptxismrenaltumors upasana sahu Group 50.pptxism
renaltumors upasana sahu Group 50.pptxismthxz2fdqxw
 
Stock Market Brief Deck FOR 31124 yt.pdf
Stock Market Brief Deck FOR 31124 yt.pdfStock Market Brief Deck FOR 31124 yt.pdf
Stock Market Brief Deck FOR 31124 yt.pdfMichael Silva
 
Planning of societal re/production in a commonist society
Planning of societal re/production in a commonist societyPlanning of societal re/production in a commonist society
Planning of societal re/production in a commonist societyStefanMz
 
Challenging Factors of Rural Women Entrepreneurs in West Bengal
Challenging Factors of Rural Women Entrepreneurs in West  BengalChallenging Factors of Rural Women Entrepreneurs in West  Bengal
Challenging Factors of Rural Women Entrepreneurs in West BengalNabarun Chakraborty
 
AUDITING FRAUDS OF AN ENGLISH COMPANY.PPTX
AUDITING FRAUDS OF AN ENGLISH COMPANY.PPTXAUDITING FRAUDS OF AN ENGLISH COMPANY.PPTX
AUDITING FRAUDS OF AN ENGLISH COMPANY.PPTXkamikazekujoh
 
Pros and Cons of Interest-Only DSCR Loans
Pros and Cons of Interest-Only DSCR LoansPros and Cons of Interest-Only DSCR Loans
Pros and Cons of Interest-Only DSCR LoansPark Place Finance LLC
 
Economic Risk Factor Update: March 2024 [SlideShare]
Economic Risk Factor Update: March 2024 [SlideShare]Economic Risk Factor Update: March 2024 [SlideShare]
Economic Risk Factor Update: March 2024 [SlideShare]Commonwealth
 
First, Second, and Third Generation Islamic Economicss
First, Second, and Third Generation Islamic EconomicssFirst, Second, and Third Generation Islamic Economicss
First, Second, and Third Generation Islamic EconomicssAsad Zaman
 
Stock Market Brief Deck FOR 3142024..pdf
Stock Market Brief Deck FOR 3142024..pdfStock Market Brief Deck FOR 3142024..pdf
Stock Market Brief Deck FOR 3142024..pdfMichael Silva
 
ANALYSIS OF BANK MANDIRI S HEALTH LEVEL BASED ON RISK PROFILE, GOOD CORPORATE...
ANALYSIS OF BANK MANDIRI S HEALTH LEVEL BASED ON RISK PROFILE, GOOD CORPORATE...ANALYSIS OF BANK MANDIRI S HEALTH LEVEL BASED ON RISK PROFILE, GOOD CORPORATE...
ANALYSIS OF BANK MANDIRI S HEALTH LEVEL BASED ON RISK PROFILE, GOOD CORPORATE...indexPub
 
14.11.2024 AMOO-MOCA African Creative Economy Summit London summary.pdf
14.11.2024 AMOO-MOCA African Creative Economy Summit London summary.pdf14.11.2024 AMOO-MOCA African Creative Economy Summit London summary.pdf
14.11.2024 AMOO-MOCA African Creative Economy Summit London summary.pdfjamie766122
 
Islamic banking in Afghanistan from start until now
Islamic banking in Afghanistan from start until nowIslamic banking in Afghanistan from start until now
Islamic banking in Afghanistan from start until nowhamidzafar6
 
BIHC Briefing Greece March 2024, with Crédit Agricole CIB
BIHC Briefing Greece March 2024, with Crédit Agricole CIBBIHC Briefing Greece March 2024, with Crédit Agricole CIB
BIHC Briefing Greece March 2024, with Crédit Agricole CIBNeil Day
 
2024.03 Strategic Resources_Pub presentation
2024.03 Strategic Resources_Pub presentation2024.03 Strategic Resources_Pub presentation
2024.03 Strategic Resources_Pub presentationAdnet Communications
 
2024.03 Strategic Resources_Pub (1). pdf
2024.03 Strategic Resources_Pub (1). pdf2024.03 Strategic Resources_Pub (1). pdf
2024.03 Strategic Resources_Pub (1). pdfAdnet Communications
 
powerpoint presentation about asian regioonalism
powerpoint presentation about asian regioonalismpowerpoint presentation about asian regioonalism
powerpoint presentation about asian regioonalismrezeraaisla
 
Swift_Maintaining Critical Standards(...).pptx.pdf
Swift_Maintaining Critical Standards(...).pptx.pdfSwift_Maintaining Critical Standards(...).pptx.pdf
Swift_Maintaining Critical Standards(...).pptx.pdfNeo4j
 
Mytilineos (OW, TP_ €46.0_sh)_ Strong organic progress 14-03-2024.pdf
Mytilineos (OW, TP_ €46.0_sh)_ Strong organic progress 14-03-2024.pdfMytilineos (OW, TP_ €46.0_sh)_ Strong organic progress 14-03-2024.pdf
Mytilineos (OW, TP_ €46.0_sh)_ Strong organic progress 14-03-2024.pdfNewsroom8
 

Último (20)

The Role of Non-Banking Financial Companies (NBFCs).pdf
The Role of Non-Banking Financial Companies (NBFCs).pdfThe Role of Non-Banking Financial Companies (NBFCs).pdf
The Role of Non-Banking Financial Companies (NBFCs).pdf
 
renaltumors upasana sahu Group 50.pptxism
renaltumors upasana sahu Group 50.pptxismrenaltumors upasana sahu Group 50.pptxism
renaltumors upasana sahu Group 50.pptxism
 
Stock Market Brief Deck FOR 31124 yt.pdf
Stock Market Brief Deck FOR 31124 yt.pdfStock Market Brief Deck FOR 31124 yt.pdf
Stock Market Brief Deck FOR 31124 yt.pdf
 
Planning of societal re/production in a commonist society
Planning of societal re/production in a commonist societyPlanning of societal re/production in a commonist society
Planning of societal re/production in a commonist society
 
Challenging Factors of Rural Women Entrepreneurs in West Bengal
Challenging Factors of Rural Women Entrepreneurs in West  BengalChallenging Factors of Rural Women Entrepreneurs in West  Bengal
Challenging Factors of Rural Women Entrepreneurs in West Bengal
 
AUDITING FRAUDS OF AN ENGLISH COMPANY.PPTX
AUDITING FRAUDS OF AN ENGLISH COMPANY.PPTXAUDITING FRAUDS OF AN ENGLISH COMPANY.PPTX
AUDITING FRAUDS OF AN ENGLISH COMPANY.PPTX
 
Pros and Cons of Interest-Only DSCR Loans
Pros and Cons of Interest-Only DSCR LoansPros and Cons of Interest-Only DSCR Loans
Pros and Cons of Interest-Only DSCR Loans
 
Economic Risk Factor Update: March 2024 [SlideShare]
Economic Risk Factor Update: March 2024 [SlideShare]Economic Risk Factor Update: March 2024 [SlideShare]
Economic Risk Factor Update: March 2024 [SlideShare]
 
First, Second, and Third Generation Islamic Economicss
First, Second, and Third Generation Islamic EconomicssFirst, Second, and Third Generation Islamic Economicss
First, Second, and Third Generation Islamic Economicss
 
Stock Market Brief Deck FOR 3142024..pdf
Stock Market Brief Deck FOR 3142024..pdfStock Market Brief Deck FOR 3142024..pdf
Stock Market Brief Deck FOR 3142024..pdf
 
Closing Remarks International Women's Day 2024
Closing Remarks International Women's Day 2024Closing Remarks International Women's Day 2024
Closing Remarks International Women's Day 2024
 
ANALYSIS OF BANK MANDIRI S HEALTH LEVEL BASED ON RISK PROFILE, GOOD CORPORATE...
ANALYSIS OF BANK MANDIRI S HEALTH LEVEL BASED ON RISK PROFILE, GOOD CORPORATE...ANALYSIS OF BANK MANDIRI S HEALTH LEVEL BASED ON RISK PROFILE, GOOD CORPORATE...
ANALYSIS OF BANK MANDIRI S HEALTH LEVEL BASED ON RISK PROFILE, GOOD CORPORATE...
 
14.11.2024 AMOO-MOCA African Creative Economy Summit London summary.pdf
14.11.2024 AMOO-MOCA African Creative Economy Summit London summary.pdf14.11.2024 AMOO-MOCA African Creative Economy Summit London summary.pdf
14.11.2024 AMOO-MOCA African Creative Economy Summit London summary.pdf
 
Islamic banking in Afghanistan from start until now
Islamic banking in Afghanistan from start until nowIslamic banking in Afghanistan from start until now
Islamic banking in Afghanistan from start until now
 
BIHC Briefing Greece March 2024, with Crédit Agricole CIB
BIHC Briefing Greece March 2024, with Crédit Agricole CIBBIHC Briefing Greece March 2024, with Crédit Agricole CIB
BIHC Briefing Greece March 2024, with Crédit Agricole CIB
 
2024.03 Strategic Resources_Pub presentation
2024.03 Strategic Resources_Pub presentation2024.03 Strategic Resources_Pub presentation
2024.03 Strategic Resources_Pub presentation
 
2024.03 Strategic Resources_Pub (1). pdf
2024.03 Strategic Resources_Pub (1). pdf2024.03 Strategic Resources_Pub (1). pdf
2024.03 Strategic Resources_Pub (1). pdf
 
powerpoint presentation about asian regioonalism
powerpoint presentation about asian regioonalismpowerpoint presentation about asian regioonalism
powerpoint presentation about asian regioonalism
 
Swift_Maintaining Critical Standards(...).pptx.pdf
Swift_Maintaining Critical Standards(...).pptx.pdfSwift_Maintaining Critical Standards(...).pptx.pdf
Swift_Maintaining Critical Standards(...).pptx.pdf
 
Mytilineos (OW, TP_ €46.0_sh)_ Strong organic progress 14-03-2024.pdf
Mytilineos (OW, TP_ €46.0_sh)_ Strong organic progress 14-03-2024.pdfMytilineos (OW, TP_ €46.0_sh)_ Strong organic progress 14-03-2024.pdf
Mytilineos (OW, TP_ €46.0_sh)_ Strong organic progress 14-03-2024.pdf
 

leukemias.ppt

  • 3. About the Disease  Leukemia, lymphoma and myeloma are cancers that originate in the bone marrow (leukemia & myeloma) or in lymphatic tissues (lymphoma).
  • 4. Different Types of Blood Cancers  Leukemia  Non-Hodgkin Lymphoma  Hodgkin Lymphoma  Myeloma  Myelodysplastic Syndromes
  • 5. What is Leukemia?  Leukemia is cancer found in the blood cells  There are many types of Leukemia  They are classified by how quickly they progress and what type of cell they affect  Leukemia is causes when there is an imbalance of healthy unhealthy blood cells in the body  This occur when one cell awry and the body begins to produce large numbers of this cell
  • 6. What Is Leukemia?  Cancer of the white blood cells  Acute or Chronic  Affects ability to produce normal blood cells  Bone marrow makes abnormally large number of immature white blood cells called blasts
  • 7. What is Leukemia  Greek word which means “white blood”  Leukemia is when cells spread rapidly and destroy living tissue.  It grows/invades the bone marrow which is the factory of blood and replaces normal blood elements with cancer cells.  Cancer cells replace all bone marrow cells which causes infection and bleeding problems.  Leukemia is basically white blood cells that don’t work well and cause trouble.
  • 8. Continued  Millions of immature and useless white blood cells are produced which makes it harder to kill cancer cells and preserve the good/healthy ones.  Leukemia causes change in cells, DNA, and gene.  If the blood matches with donator then you are curried.  Bone marrow is spongy tissue that fills in the center core of bone.  There are 4 different types of Leukemia.
  • 9. Types of Leukemia  Based on how quickly the disease develops it is classified as either acute or chronic  In Acute Leukemia the white blood cells tend to develop more rapidly and very immature  In Chronic Leukemia the cells tend to develop more slowly  They are also classified by which type of white bloods cells are affected  If the lymphoid cells are affected the disease is referred to as Lymphocytic Leukemia  If the myeloid cells are affected it is called Myelongenous Leukemia
  • 10. Types of Leukemia  Acute lymphoblastic Leukemia (ALL)  Acute myeloblastic Leukemia (AML)  Chronic lymphocyte Leukemia (CLL)  Chronic myeloid Leukemia (CML)
  • 11. Demographics of Leukemia Patients (2001 Data) ALL 11% CLL 26% AML 31% CML 15% others 17% Total Reported Cases = 31,500 Sources from Leukemia, Lyphoma, Myeloma Facts 2001 CLL=Chronic Lymphocytic ALL=Acute Lymphocytic CML=Chronic Mylogenous AML=Acute Mylogenous
  • 12. Chronic and Acute Chronic Leukemia:  Progress slowly (runs a slow course)  Not immediately fatal. Acute Leukemia:  Progress rapidly (runs a fast course)  Life expectancy short without treatment.
  • 13. Lymphocyte and Myeloid Lymphocyte:  Increase in white blood cells produced in lymph nodes and bone marrow.  Strikes without any warning. Myeloid:  Increase in white blood cells produced exclusively in the bone marrow.  Strikes without any warning.
  • 14. Acute Myeloid Leukemia (AML):  Mixed group of disease  It means “marrow like” and in this context it simply means arising from developing blood cells.  This type of leukemia runs a rapid course.
  • 15. Acute Lymphoblast Leukemia (ALL):  Group of different diseases  A complexity of which is still trying to be unraveled  Reached a point where not all are being treated the same.  This type of Leukemia runs a rapid course.
  • 16. Chronic Myeloid Leukemia (CML):  Characterized by increased production of granulocytes in the bone marrow.  Usually associated with a specific chromosomal abnormality called the Philadelphia chromosome  Progresses slowly
  • 17. Chronic Lymphocyte Leukemia (CLL):  This type of cancer is so rare it could be said not to arise at all in the first two decades of life.  Starts of in the Bone marrow  This type of cancer runs a slow course giving more time to live.
  • 18. Risk Factors  As of now we do not know the exact cause of Leukemia  Exposure to these have been identified as risk factors  High energy radiation  Some genetic syndromes  People working with chemical benzene for a long period of time
  • 19. Causes  High level radiation/toxin exposure  Viruses  Genes  Chemicals  Mostly unknown  Can’t be caught
  • 20. Development of Leukemia in the Bloodstream Stage 1- Normal Stage 2- Symptoms Stage 3- Diagnosis Stage 4- Worsening Stage 5a- Anemia Stage 5b- Infection Legend White Cell Red Cell Platelet Blast Germ Sources from Leukemia, by D. Newton and D. Siegel
  • 21. Effects On the Body  Attacks the immune system  Infections  Anemia  Weakness  No more regular white blood cells, red blood cells, and platelets  Blasts clog blood stream and bone marrow
  • 22. Symptoms  When there are excessive white blood cells - -> Infections  When there are few red blood cells: Paleness --> Anemia  When there are few platelets --> Excessive bleeding
  • 23. Signs Of Leukemia Most of the symptoms of leukemia are similar to those of a common illness such as the flu. The symptoms will vary according to the type of leukemia.  Tired  Frequent infections  Easy bruising or bleeding  Bone tenderness  Headache  Enlarged lymph nodes  Low red blood count  Pale skin  Poor appetite
  • 24. Tests For Diagnosis  Finger prick  Blood sample  Blood dye  Bone marrow sample  Spinal Tap/Lumbar Puncture
  • 25. Diagnosis  As immature cells increase in the body leads to lower amounts of red blood cells and platelet cells  The low amounts of red blood cells cause patient to be tired and pale  Low amounts of platelet cells cause the patient to easily bruise or bleed  During a physical exam the doctor detects swollen spleen, liver, or lymph nodes  Then there is a blood test conducted to see if it is leukemia  The type of Leukemia is determined after bone marrow is extracted and tested
  • 26. Diagnosis  Most commonly leukemia is diagnosed by a blood test to count the number of red cells, white cells and platelets. A biopsy of the bone marrow may also be performed
  • 27. Pictures Of Blood Normal human blood White Cell Red Cell Platelet Blood with leukemia Blasts Red Cell Platelet White Cell Sources from Arginine.umdnj.edu Sources from beyond2000.com
  • 29. Diagnosis Requires all of the following diagnostic components: a) Documentation of bone marrow infiltration b) Myeloid origin of the leukemic cells c) FAB/WHO classification of the leukemia d) Karyotypic analysis
  • 30. Differential Diagnosis  chronic myelogenous leukemia  other myeloproliferative disorders  reactive leukocytosis: leukemoid reaction  acute leukemia
  • 33. BCR-ABL p210 Fusion Protein Activity  Higher tyrosine kinase activity. – Increases progenitor cells, reduces the pool of stem cells. Semin Hematol 1988;25:1-19. – Defective cytoadherence. Hematol Oncol Clin North Am 1988;12:1-29. – Suppression of apoptosis. Blood 1994;83:1575-85.
  • 34. BCR-ABL p210 Fusion Protein Evidence of its role in CML  In vitro: cause factor-independent, leukemogenic cell growth in hematopoietic cell lines.  In vivo: generate in mice CML-like syndrome. Science 1990;247:824-30.
  • 35. FAB Classifications M0: minimally differentiated M1: without maturation M2: with maturation. May have t(8;21) translocation. M3: promyelocytic. Good prognosis. Can be associated w/ t(15;17). M4: myelomonocytic; assoc. w/ t(16;16) or inv(16)(p13q22). M5: monoblastic M6: erythroleukemia M7: megakaryoblastic. Poor overall survival.
  • 45. Clinical Course  Median survival: 3.5~8 yr.  Chronic phase: 3~4 yr.  Accelerated phase (15%): 3~6 mo, then enters acute phase.  Acute phase (blast crisis), 25% in each year, findings: blasts > 30%, cytogenetic changes other than Ph chromosome, progression likes acute leukemia. 70% enters AML, 30% ALL.
  • 46. Prognosis “Good risk”: favorable karyotype, including t(8;21), t(15;17), inv(16)/t(16;16)/del(16q) or FAB subtype M3 “Poor risk”: adverse karyotype or resistant disease after first course of chemo (i.e. >15% blasts in post-tx bone marrow bx) 5-yr survival for good, standard, and poor risk patients 70, 48, and 15% respectively. Relapse rates are 33, 50, and 78% respectively.
  • 47. Treatment  As of yet there is no cure for Leukemia  Many advances have been made in the past couple years  The survival rate of children with Acute Lymphocytic is around 82% Treatments include:  Chemotherapy  Radiotherapy  Immunotherapy  Bone marrow transplant
  • 48. Research  New drugs  Cord blood and planceta
  • 49. Treatment  Depending on the type of cancer treatments may vary. Treatments of leukemia may include chemotherapy, radiation therapy, or bone marrow transplant. They also treat leukemia patients with the infusion of healthy blood cells and platelets. During and after the treatment blood counts are done to see if the patient is being controlled or in remission.
  • 50. Treatments  Blood and marrow stem cell transplantation.  Research.  Development of new drugs.  Immunotherapy.  Vaccines.  Reversal of multidrug resistance.  Gene therapy.
  • 51. Management (1)  Chronic phase – Hydroxyurea or busulfan, relieves symptoms and control of disease. – Interferon-a: 20% cytogenetic response, prolongation of survival. . It can gain 20 more months survival than C/T. This advantage must be weighed against its significant side effects.
  • 52. Management (2) BMT or PBSCT  Allogeneic bone marrow transplantation in the chronic phase is the only therapy known to cure CML 5YS > 50%, relapse < 20%, 20~40% BMT related death in the first year.  It should be done as soon as possible for patients – Chronic phase. – <50 years old. – Has an HLA-identical sibling.
  • 53. Management (3) STI571  STI 571:Inhibitors of the BCR-ABL fusion proteins (tyrosine kinase)  After six months of therapy with Glivec (STI571), preliminary findings showed that half of 290 patients tested were improving. They had what's known as a cytogenic remission -- a reduction in the 'Philadelphia Chromosome' which causes the disease.  "In these patients we found a very high response rate, there was some response seen in 91 percent of the patients," said Dr. Talpaz of the M.D. Anderson Cancer Center. "Some of the patients returned to the chronic phase of the disease."
  • 54. Allogeneic Stem Cell Transplantation  eradicates of the marrow cells (marrow- ablating C/T or R/T)  implantation of allogeneic stem cells  homing of the stem cells to the marrow cavity  growth of the stem cells and recovery of the blood cells
  • 55. Complications of SCT  rejection, graft failure  graft-versus-host disease  infection  VOD  obliterative bronchiolitis  sepsis  relapse of disease
  • 56. GVHD (Graft versus Host Disease)  Immunologic reaction of donor lymphocytes to “foreign” antigens present on the surface of host cells  “foreign” antigens: – HLA antigens – “minor” antigens not detected by current typing techniques
  • 57. Acute GVHD (1) incidence  Within the first 3 months after BMT  20~50% of HLA-identical, 80% of HLA non- identical recipients  incidence increases with – patient age – degree of HLA disparity
  • 58. Acute GVHD (2)manifestations  Histology: lymphocytic infiltration of the epidermis and GI tract  fever  dermatitis: diffuse macular dermatitis, bullas, desquamation  enteritis: cramping abdominal pain, watery to bloody diarrhea  hepatitis: jaundice, cholestasis, hepatocellular necrosis  infection: frequently related to mortality  hyperacute GVHD (no prophylaxis): 7 days after BMT: exfoliative dermatitis, shock, hyperpyrexia
  • 59. Chronic GVHD (1) incidence  develops > 3 months after BMT  20~50% of allografts, usually following acute GVHD  20~30% develops de novo, without prior acute GVHD
  • 60. Chronic GVHD (2) manifestations like collagen diseases  skin: pigmentation, sclerosis  mucosa: lichenoid oral plaque, esophagitis, polyserositis, oral and eye sicca syndrome  liver: elevated ALP and GOT in 90% cases  chronic wasting due to anorexia  chronic pulmonary disease: 10~20% (diffuse interstitial pnuemonitis and obliterative bronchiloitis)  death usually caused by infection, low mortality related to de novo onset & less tissue involvement.
  • 61. Blast Crisis  30% ALL, 70% AML  Treatment likes de novo acute leukemia with poor success.  Chance of achieving remission is possible in ALL, which may last 4~8 months, but low in AML.  Survival is usually 2~4 months.
  • 62. CML in Blast Crisis